首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
【24h】

Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.

机译:人体恶性积液中的活化凝血因子及其对癌细胞转移和治疗的作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have shown that the thrombin G-protein coupled receptors (GPCR) designated as protease-activated receptors (PAR-1) are expressed in primary cancer cells isolated from peritoneal and pleural malignant effusions. Here, our main goal was to evaluate several coagulation and thrombin activation effectors and markers in a series of 136 malignant effusions from cancer patients with gastrointestinal, lung and mammary carcinomas. All these patients present a highly activated coagulation system in blood and their malignant effusions, as indicated by high levels of prothrombin F1.2 fragments and D-dimers. Notably, we detected in the effusions all the coagulation factors of the tissue factor pathway inducing thrombin activation, namely factors VII, V, X and II, as well as high VEGF levels and IGF-II in mature and precursor forms. Fibrin clot formation also correlated with higher levels of free ionized calcium (iCa), suggesting that iCa and its binding protein albumin are regulatory factors for fibrinogenesis ineffusions. Consequently, thrombin, VEGF and IGFII appear to converge in the promotion of survival and invasivity of the metastatic cancer cells from blood to the malignant effusions. Thus, we add new insights on the interconnections between blood coagulation disorders in cancer patients and thrombin activation in malignant effusions, including their functional interaction with PAR in metastatic cancer cells. Based on these data we propose to counteract the metastatic cascades by targeted invalidation of key effectors of the coagulation system. Therefore, potential therapeutic approaches include the application of thrombin protease inhibitors, VEGF-blocking antibodies, and drugs targeting the VEGF and thrombin signaling pathways, such as tyrosine kinase or GPCR inhibitors.
机译:我们已经表明,被称为蛋白酶激活受体(PAR-1)的凝血酶G蛋白偶联受体(GPCR)在从腹膜和胸膜恶性积液分离的原发癌细胞中表达。在这里,我们的主要目标是评估胃肠道,肺癌和乳癌癌症患者的一系列136次恶性积液中的几种凝血和凝血酶激活效应子及标记物。所有这些患者在血液及其恶性积液中均表现出高度活化的凝血系统,凝血酶原F1.2片段和D-二聚体水平高表明了这一点。值得注意的是,我们在积液中检测到所有诱导凝血酶活化的组织因子途径的凝血因子,即VII,V,X和II因子,以及成熟和前体形式的高VEGF水平和IGF-II。纤维蛋白凝块的形成还与较高水平的游离离子钙(iCa)相关,这表明iCa及其结合蛋白白蛋白是纤维蛋白生成注入的调节因子。因此,凝血酶,VEGF和IGFII似乎在促进转移性癌细胞从血液到恶性积液的存活和侵袭性方面趋于融合。因此,我们为癌症患者的凝血功能障碍和恶性积液中的凝血酶活化之间的相互关系增加了新见解,包括它们与转移性癌细胞中PAR的功能相互作用。基于这些数据,我们建议通过凝血系统关键效应子的靶向无效来抵消转移级联。因此,潜在的治疗方法包括凝血酶蛋白酶抑制剂,VEGF阻断抗体和靶向VEGF和凝血酶信号通路的药物(例如酪氨酸激酶或GPCR抑制剂)的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号